Top 10 Pharmaceutical Companies 2017

Top 10 Pharmaceutical Companies 2017

The global pharmaceutical market was estimated in USD 1.1 trillion in 2016. The global market is highly mature and consolidated. The top-10 pharmaceutical companies in this market had share of around 40% in 2016 and approximately 50% considering the top-15. A comparative analysis of the top-15 organizations was used to develop a ranking for these … Continue reading Top 10 Pharmaceutical Companies 2017

Advertisements
Roche logo

Perjeta regimen of Roche helped people with an aggressive type of early breast cancer live longer, Phase III APHINITY study shows

March 2, 2017 Roche, Breast European Adjuvant Study Team (BrEAST), the Breast International Group (BIG) and Frontier Science Foundation (FS) have announced positive results from the phase III APHINITY study, which met its primary endpoint and showed that adjuvant (after surgery) treatment with the combination of Perjeta® (pertuzumab), Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen) … Continue reading Perjeta regimen of Roche helped people with an aggressive type of early breast cancer live longer, Phase III APHINITY study shows

Top Pharma News - IgeaHub

Top Pharma News | February – March 2017

Amgen Announces the Efficay of Repatha® (Evolocumab) for Reducing the Risk of Cardiovascular Events February 2, 2017 Amgen has announced that the FOURIER (Further Cardiovascular OUtcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) trial evaluating whether Repatha® (evolocumab) minimizes the risk of cardiovascular events in patients with clinically evident atherosclerotic cardiovascular disease (ASCVD) met its primary composite endpoint (cardiovascular death, … Continue reading Top Pharma News | February – March 2017

Roche logo

Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer

21 February 2017 Roche has announced that the European Commission has granted a conditional marketing authorisation for Alecensa® (alectinib) as monotherapy for treating adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib. Within one year of treatment, most people with ALK-positive NSCLC develop resistance to the current … Continue reading Roche receives EU approval of Alecensa (alectinib) for people with previously treated ALK-positive non-small cell lung cancer

World's Most Admired Pharmaceutical Companies 2017

World’s Most Admired Pharmaceutical Companies 2017

Reputation is extremely important for Pharmaceutical Companies. Like every year, Fortune collaborated with Korn Ferry Hay Group on the survey of corporate reputations. To determine the best-regarded companies in 51 industries, Korn Ferry Hay Group evaluated 680 companies in 28 countries. Executives, directors, and analysts have been asked to rate enterprises in their own industry, here … Continue reading World’s Most Admired Pharmaceutical Companies 2017

Best Selling Oncology Drugs 2016 - Igeahub - Luca Dezzani

Best Selling Oncology Drugs 2016

The top-ten oncology drugs accounted for 36% of the total oncology drugs market. The list is headed by Avastin, an oncology product manufactured by Roche

Best Pharma Companies at a Glance: Roche - Igeahub.com

Best Pharma Companies at a Glance: Roche

Hoffmann-La Roche (Roche) develops, manufactures and deliver innovative therapeutics and diagnostic instruments and tests. The company operates through two business segments: Pharmaceuticals and Diagnostics. Pharmaceuticals division is further categorized on the basis of therapeutic areas into oncology, immunology, infectious diseases, ophthalmology, neuroscience and other therapeutic areas.

Roche logo

FDA grants Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review for the treatment of advanced bladder cancer

09 January 2017 Roche has announced that the U.S. Food and Drug Administration (FDA) has accepted the  supplemental Biologics License Application (sBLA) of the company and granted Priority Review for TECENTRIQ® (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are ineligible for cisplatin chemotherapy, and are either previously … Continue reading FDA grants Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) Priority Review for the treatment of advanced bladder cancer

Igeahub.com - Top Pharma News - Luca Dezzani

Top Pharma News – December 2016

ABOUND Data Explores Safety and Efficacy of ABRAXANE® for the Treatment of Patients with Lung Cancer Dec 6, 2016 Celgene Corporation has announced interim results from the ABOUND clinical trial program evaluating the use of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in patients with advanced non-small cell lung cancer (NSCLC). Interim data presented from the … Continue reading Top Pharma News – December 2016

Roche logo

Roche’s emicizumab for the Treatment of haemophilia A meets primary endpoint in phase III study

22 December 2016 Roche has announced that the primary endpoint has been met for the phase III HAVEN 1 study assessing emicizumab prophylaxis in people with haemophilia A and inhibitors to factor VIII. The study revealed a statistically significant reduction in the number of bleeds over time in people treated with emicizumab prophylaxis compared to … Continue reading Roche’s emicizumab for the Treatment of haemophilia A meets primary endpoint in phase III study